Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer
Xentuzumab + abemaciclib + ETs demonstrated manageable tolerability and promising efficacy, especially in patients with breast cancer and non-visceral metastases.
Authors
- M. Vidal
- Anthony Gonçalvès (ORCID: https://orcid.org/0000-0001-7570-7439)
- Hiroji Iwata (ORCID: https://orcid.org/0000-0002-0242-4718)
- Molly Catherine Hardebeck (ORCID: https://orcid.org/0009-0009-9641-7137)
- Nancy Forman
- Don Yee
- Yasuhiro Fukuyama
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Agostina Stradella (ORCID: https://orcid.org/0000-0002-2307-8869)
- Patricia LoRusso (ORCID: https://orcid.org/0000-0001-7144-036X)
- Robert M. Lorence (ORCID: https://orcid.org/0009-0001-6019-165X)
- Marie Paule Sablin
- Marta Puig
Institutions
- Breast Cancer Research Foundation (US)
- Yale University (US)
- Hospital Clínic de Barcelona (ES)
- Aichi Cancer Center (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105863
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00